Loading clinical trials...

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea

NCT00157950•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.

Eligibility

Age

9 - 23 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Girls ages 9 to 15 years (must not yet have had coitarche)
•Healthy females ages 16 to 23 years (individuals with a lifetime history of 0 to 3 male or female sexual partners)

Exclusion Criteria

•All Subjects:
•History of known prior vaccination with an HPV vaccine.
•Women Ages 16 to 23 Only:
•Individuals with any prior history of genital warts or treatment for genital warts.
•Individuals with \> 3 lifetime male or female sexual partners.

Key Dates

Start Date

October 1, 2005

Primary Completion Date

June 1, 2006

Completion Date

June 1, 2006

Last Updated

February 4, 2016

Enrollment

176

ACTUAL participants

Conditions

Papillomavirus Infections

Interventions

Gardasil™

BIOLOGICAL

Placebo

BIOLOGICAL

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689

Papillomavirus Infections

View study

COMPLETEDNA

Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers

NCT06854354

Papillomavirus InfectionsPapillomavirus Vaccines

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

Inclusion Criteria

Exclusion Criteria

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo.

Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination